I am thrilled to share that BrightInsight and CSL Behring formally announced our global partnership to provide digitally-enhanced treatment experiences and regulated digital health offerings to support CSL Behring therapies.
As COVID-19 continues to have a profound impact on both global health and economies, we are grateful to continue to grow our list of top tier biopharma customers to accelerate the transformation of healthcare through digital.
CSL Behring, the world’s 3rd largest biotechnology company, is leveraging our regulated BrightInsight Platform to manage and support its growing digital health portfolio of solutions focused on enhancing the treatment experiences of patients with rare and serious diseases.
After conducting a rigorous evaluation, CSL Behring selected BrightInsight because we are the only regulated solution with a robust Quality Management System and comprehensive privacy and security certifications.
Here are a few more details on our partnership:
"After conducting a rigorous evaluation, we selected BrightInsight because it has the only regulated solution with a robust Quality Management System and comprehensive privacy and security certifications. BrightInsight’s Platform allows us to focus on therapeutic innovation, rather than the underlying digital technology,” said Brian Johnson, Director, Digital Health, CSL Behring. “CSL Behring is committed to delivering on our promise to support and empower our patients through digital engagement and we are excited to launch the first offering later this year."
We are honored to be partnering with CSL Behring to enhance treatment experiences for such a deserving patient population and look forward to sharing more news on our joint projects over the coming months.